Filing Analysis
Nephros, Inc. filed an 8-K to announce the release of its second quarter 2026 financial results. The filing serves as a formal notice that earnings data has been furnished via press release.
📋 Key Facts
- Report date: August 6, 2026
- Subject matter: Disclosure of Q2 2026 financial results
- The information was furnished pursuant to Item 2.02 and is not considered 'filed' for liability purposes under Section 18.
Nephros, Inc. filed an 8-K to report the publication of an updated 2026 Corporate Presentation on its website. The information was furnished under Item 7.01 and is not deemed 'filed' for liability purposes under Section 18 of the Exchange Act.
📋 Key Facts
- The company posted an updated 2026 Corporate Presentation on June 12, 2026.
- The presentation is attached as Exhibit 99.1.
- The filing was signed by Judy Krandel, Chief Financial Officer.
Nephros, Inc. announced its first quarter 2026 financial results via a press release on May 7, 2026. The filing is a standard quarterly update furnished under Item 2.02.
📋 Key Facts
- Reported Q1 2026 financial results on May 7, 2026.
- Information furnished under Item 2.02 (Results of Operations and Financial Condition).
- Included Exhibit 99.1, the official press release regarding financial performance.
Nephros, Inc. updated its 2026 Corporate Presentation on its website and furnished the presentation as an exhibit to this 8-K filing. This is a routine disclosure under Regulation FD to ensure all investors have access to the same company information.
📋 Key Facts
- The filing was made on March 27, 2026, under Item 7.01 Regulation FD Disclosure.
- The updated 2026 Corporate Presentation is included as Exhibit 99.1.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The report was signed by Judy Krandel, Chief Financial Officer.
Nephros, Inc. entered into a new License and Supply Agreement with Medica S.p.A., replacing a previous agreement from 2023. The deal involves an exclusive license for Medisulfone ultrafiltration technology products and includes significant minimum annual purchase commitments through 2030.
🚩 Red Flags
- Significant long-term minimum purchase obligations (totaling over €28M in commitments) which create fixed cash outflows regardless of sales volume.
📋 Key Facts
- Entered into License and Supply Agreement with Medica S.p.A. on November 21, 2025.
- The agreement replaces a prior license agreement dated December 11, 2023.
- Nephros receives an exclusive license to market, promote, distribute, and sell Products in the Territory.
- Medica receives an exclusive license under Nephros's IP to manufacture the Products.
- Minimum annual purchase commitments from Nephros: €4.976M (2026), €5.349M (2027), €5.750M (2028), €6.000M (2029), and €6.300M (2030).
- Agreement term extends through December 31, 2030.
- Nephros maintains a right to terminate for convenience with 90 days' notice.
Nephros, Inc. filed an 8-K to furnish its second quarter 2025 financial results via a press release dated August 7, 2025.
📋 Key Facts
- The filing is a standard disclosure of quarterly financial results (Item 2.02).
- Results pertain to the second quarter of 2025.
- Press release was issued on August 7, 2025 and furnished as Exhibit 99.1.
Nephros, Inc. held its 2025 Annual Meeting of Stockholders on June 16, 2025. The meeting resulted in the election of a new director, ratification of the company's independent auditor, and an advisory vote on executive compensation.
📋 Key Facts
- Held 2025 Annual Meeting of Stockholders on June 16, 2025.
- Elected Lisa Nettis to the Board of Directors for a three-year term expiring in 2028 (received 6,066,124 'For' votes).
- Ratified Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year ending December 31, 2025.
- Approved executive officer compensation on an advisory (non-binding) basis.
Nephros, Inc. filed an 8-K to furnish its first quarter 2025 financial results via a press release. The filing contains no specific financial data or qualitative disclosures within the text itself.
📋 Key Facts
- Report date: May 8, 2025
- The company disclosed Q1 2025 financial results through an attached press release (Exhibit 99.1).
- Filed under Item 2.02 (Results of Operations and Financial Condition).
Nephros, Inc. announced that Alisa Lask will not stand for re-election to the Board of Directors at the upcoming annual meeting on June 16, 2025. The departure is characterized as a non-dispute event.
🚩 Red Flags
- None identified in this specific filing; departure is non-dispute related.
📋 Key Facts
- Alisa Lask notified the Board she will not seek re-election at the 2025 Annual Meeting scheduled for June 16, 2025.
- Ms. Lask's term expires upon the conclusion of the annual meeting.
- The company explicitly stated the decision was not due to any disagreement regarding operations, policies, or practices.
Nephros, Inc. has furnished an updated 2024 Corporate Presentation via its website as of March 31, 2025.
📋 Key Facts
- The company posted an updated 2024 Corporate Presentation on its corporate website on March 31, 2025.
- The presentation is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Nephros, Inc. filed an 8-K to furnish its fourth quarter and fiscal year 2024 financial results via a press release. This is a routine earnings announcement filing.
📋 Key Facts
- Report date: March 6, 2025
- The company disclosed Q4 and FY 2024 financial results through Exhibit 99.1.
- Information was furnished pursuant to Item 2.02 of Form 8-K.
Nephros, Inc. entered into an amendment to the employment agreement of CFO Judith Krandel on February 26, 2025. The amendment includes significant new stock option grants tied to both time-based vesting and specific revenue-growth milestones related to a potential strategic transaction.
🚩 Red Flags
- Performance-based equity tied specifically to a 'strategic transaction' suggests management is incentivized toward an M&A event or significant restructuring.
- Significant increase in executive compensation (bonus target and options) during a period where the company may be seeking strategic exits.
📋 Key Facts
- Amendment to CFO Judith Krandel's Letter Agreement dated July 28, 2023.
- Grant of two separate 10-year stock options: 54,359 and 58,961 shares under the 2024 Equity Incentive Plan.
- First set of options (54,359 shares) vests over time: 25% on the first anniversary of grant, remaining 75% in equal quarterly installments.
- Second set of options (58,961 shares) is contingent upon a 'strategic transaction' resulting in revenue increases of at least $4M (if in FY2025) or $4M/25% of projected revenue (if post-FY2025).
- Annual performance bonus target increased to 30% of annualized base salary.
- Accelerated vesting clause: All options become fully vested upon termination by the Company without 'Cause'.
Nephros, Inc. filed an 8-K to furnish its third quarter 2024 financial results via a press release dated November 7, 2024.
📋 Key Facts
- The filing is a standard disclosure of quarterly earnings (Item 2.02).
- Financial results for Q3 2024 were disclosed on November 7, 2024.
- The report was signed by CFO Judy Krandel on November 13, 2024.
Nephros, Inc. has released an updated 2024 Corporate Presentation via its website and furnished it as an exhibit in this 8-K filing.
📋 Key Facts
- The company posted an updated 2024 Corporate Presentation on August 26, 2024.
- The presentation is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Nephros, Inc. held its 2024 Annual Meeting of Stockholders on May 23, 2024, where several key matters were approved by shareholders.
📋 Key Facts
- Stockholders elected Arthur H. Amron and Oliver Spandow to the Board of Directors for three-year terms expiring in 2027.
- Ratification of Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Approval of the Nephros, Inc. 2024 Equity Incentive Plan.
- Advisory (non-binding) approval of compensation for named executive officers.
Nephros, Inc. filed an 8-K to announce the release of its first quarter 2024 financial results via press release.
📋 Key Facts
- The filing is a standard disclosure of quarterly earnings (Item 2.02).
- Financial results for Q1 2024 were disclosed on May 9, 2024.
- The report was signed by Judy Krandel, Chief Financial Officer.
Nephros, Inc. filed an 8-K to furnish its 2024 Corporate Presentation, which was presented at the Planet MicroCap Showcase: VEGAS 2024 on May 1, 2024.
📋 Key Facts
- The filing is a Regulation FD disclosure regarding a corporate presentation.
- Presentation date: May 1, 2024.
- Event: Planet MicroCap Showcase: VEGAS 2024.
Nephros, Inc. filed an 8-K to furnish its fourth quarter and fiscal year 2023 financial results via a press release. The filing is a routine disclosure of quarterly earnings.
📋 Key Facts
- The company disclosed Q4 and FY 2023 financial results on March 7, 2024.
- Financial results were released via a press release (Exhibit 99.1).
- The filing was signed by CFO Judy Krandel.